Royalty Pharma plc
For the period ended Dec 31, 2025. Filed Feb 11, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 11, 2026
RPRX$68.77+2.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Rule 10b5-1 Trading Arrangements
During the fourth quarter of 2025, no director or Section 16 officer adopted, modified orterminated any Rule 10b5-1 plans or non-Rule 10b5-1 trading arrangements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.